Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16398139 | 1.00 | TSHR (0.57) | TSHRCYP2C19SMN1; SMN2NPC1RAB9A | |
| SCHEMBL22849511 | 0.88 | ALDH1A1 (0.55) | TSHRSMN1; SMN2NPC1RAB9ACTSL | |
| SCHEMBL3398972 | 0.88 | ALDH1A1 (0.55) | TSHRSMN1; SMN2NPC1RAB9ACTSL | |
| SCHEMBL25877951 | 0.85 | ALDH1A1 (0.45) | TSHRCTSLCTSBCTSKAGTR2 | |
| SCHEMBL22849113 | 0.85 | AGTR2 (0.46) | TSHRCTSLCTSBCTSKAGTR2 | |
| SCHEMBL23728448 | 0.85 | CTSL (0.45) | TSHRCYP2C19SMN1; SMN2CTSLCTSB | |
| SCHEMBL22835418 | 0.85 | AGTR2 (0.46) | TSHRCTSLCTSBCTSKAGTR2 | |
| SCHEMBL23744430 | 0.85 | CTSL (0.45) | TSHRCYP2C19SMN1; SMN2CTSLCTSB | |
| SCHEMBL17019782 | 0.83 | TSHR (0.58) | TSHRCTSLCTSBCTSK | |
| SCHEMBL1928095 | 0.83 | TSHR (0.58) | TSHRCTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| WO-2021158634-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2014196328-A1 | HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | 日本理化学工業株式会社 (JP) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TSHR 3319/4885CYP2C19 3990/4885SMN1; SMN2 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.